Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Prelude Therapeutics (PRLD) reported Q3 2024 financial results and clinical updates. Key highlights include interim data from Phase 1 study of PRT3789, showing clinical proof of concept in SMARCA4-mutated cancers. The company initiated Phase 1 trial for PRT7732 and presented preclinical data from its Precision ADC platform. Financial position remains strong with $153.6M cash runway into 2026. Q3 net loss was $32.3M ($0.43/share). R&D expenses increased to $29.5M from $26.3M year-over-year, while G&A expenses rose to $7.9M from $7.1M.
Prelude Therapeutics (PRLD) ha riportato i risultati finanziari e gli aggiornamenti clinici del terzo trimestre del 2024. I principali punti salienti includono i dati preliminari dallo studio di Fase 1 di PRT3789, che mostrano una prova clinica di concetto nei tumori mutati del gene SMARCA4. L'azienda ha avviato la sperimentazione clinica di Fase 1 per PRT7732 e ha presentato dati preclinici dalla sua piattaforma Precision ADC. La posizione finanziaria rimane solida con una liquidità di $153,6 milioni fino al 2026. La perdita netta del terzo trimestre è stata di $32,3 milioni ($0,43 per azione). Le spese per R&D sono aumentate a $29,5 milioni rispetto ai $26,3 milioni dell'anno precedente, mentre le spese per G&A sono salite a $7,9 milioni rispetto ai $7,1 milioni.
Prelude Therapeutics (PRLD) informó sobre los resultados financieros y las actualizaciones clínicas del tercer trimestre de 2024. Los puntos clave incluyen datos interinos del estudio de Fase 1 de PRT3789, que muestran prueba clínica de concepto en cánceres mutados por SMARCA4. La compañía inició el ensayo de Fase 1 para PRT7732 y presentó datos preclínicos de su plataforma Precision ADC. La situación financiera sigue siendo sólida con $153,6 millones en efectivo proyectado hasta 2026. La pérdida neta del tercer trimestre fue de $32,3 millones ($0,43 por acción). Los gastos de I+D aumentaron a $29,5 millones desde $26,3 millones en comparación con el año anterior, mientras que los gastos de G&A subieron a $7,9 millones desde $7,1 millones.
프렐류드 테라퓨틱스 (PRLD)가 2024년 3분기 재무 결과와 임상 업데이트를 발표했습니다. 주요 하이라이트로는 SMARCA4 변이 암에서 임상적 개념 증명이 나타난 PRT3789의 1상 연구 Interim 데이터가 포함됩니다. 회사는 PRT7732에 대한 1상 시험을 시작했으며, Precision ADC 플랫폼의 전임상 데이터를 발표했습니다. 재무 상태는 2026년까지 $153.6M의 현금 잔여금을 보유한 강력한 상태를 유지하고 있습니다. 3분기 순손실은 $32.3M($0.43/주)였습니다. 연구개발 비용은 전년 대비 $26.3M에서 $29.5M으로 증가했으며, 일반 및 관리비는 $7.1M에서 $7.9M로 증가했습니다.
Prelude Therapeutics (PRLD) a publié les résultats financiers et les mises à jour cliniques pour le troisième trimestre 2024. Les éléments clés comprennent des données intermédiaires de l'étude de phase 1 de PRT3789, montrant une preuve clinique de concept dans les cancers mutés SMARCA4. La société a lancé un essai de phase 1 pour PRT7732 et a présenté des données précliniques de sa plateforme Precision ADC. La situation financière reste solide avec une trésorerie de 153,6 millions de dollars jusqu'en 2026. La perte nette pour le troisième trimestre s'élevait à 32,3 millions de dollars (0,43 $/action). Les dépenses de R&D ont augmenté à 29,5 millions de dollars contre 26,3 millions de dollars l'année précédente, tandis que les dépenses générales et administratives ont augmenté à 7,9 millions de dollars contre 7,1 millions de dollars.
Prelude Therapeutics (PRLD) hat die finanziellen Ergebnisse und klinischen Updates für das dritte Quartal 2024 veröffentlicht. Zu den wichtigsten Punkten gehören die vorläufigen Daten aus der Phase-1-Studie von PRT3789, die einen klinischen Nachweis des Konzepts bei SMARCA4-mutierten Krebserkrankungen zeigen. Das Unternehmen hat die Phase-1-Studie für PRT7732 gestartet und vorläufige Daten von seiner Precision ADC-Plattform präsentiert. Die finanzielle Lage bleibt stark mit einem Cash-Bestand von 153,6 Millionen US-Dollar bis 2026. Der Nettoverlust im dritten Quartal betrug 32,3 Millionen US-Dollar (0,43 US-Dollar/Aktie). Die F&E-Ausgaben stiegen im Jahresvergleich von 26,3 Millionen US-Dollar auf 29,5 Millionen US-Dollar, während die allgemeinen Verwaltungskosten von 7,1 Millionen US-Dollar auf 7,9 Millionen US-Dollar anstiegen.
- Clinical proof of concept achieved for PRT3789 with confirmed partial responses in NSCLC and esophageal cancer patients
- Strong cash position of $153.6M providing runway into 2026
- Successful initiation of Phase 1 trial for oral SMARCA2 degrader PRT7732
- Established collaboration with Pfizer Ignite while retaining full ownership rights
- Increased net loss to $32.3M from $30.6M year-over-year
- Higher R&D expenses at $29.5M compared to $26.3M in prior year
- Increased G&A expenses to $7.9M from $7.1M year-over-year
Insights
The clinical data from PRT3789 demonstrates promising early efficacy with 4 confirmed partial responses out of 26 evaluable patients with SMARCA4 mutations, particularly in NSCLC and esophageal cancers. The drug's safety profile appears favorable both as monotherapy and in combination with docetaxel. The advancement of two differentiated SMARCA2 degraders (PRT3789 and PRT7732) positions Prelude as a leader in this novel therapeutic approach.
The company's financial position is solid with
The Q3 financials reveal strategic resource allocation toward clinical development. The
The current cash position of
Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, demonstrating clinical proof of concept
Initiated a Phase 1 trial for PRT7732, its first-in-class oral SMARCA2 degrader in patients with SMARCA4-mutated cancers
Presented first preclinical data from its next generation degrader antibody conjugate (Precision ADC) platform
Interim phase 1 clinical data with potentially best-in-class CDK9 inhibitor, PRT2527, in hematological malignancies to be presented at the American Society of Hematology Annual Meeting in December 2024
Current cash runway into 2026 with
WILMINGTON, Del., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the third quarter ended September 30, 2024 and provided an update on its clinical development pipeline and other corporate developments.
“Our third quarter was marked by dedicated execution and the achievement of essential milestones for our lead clinical programs targeting SMARCA2,” stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. “We have demonstrated the first-ever clinical proof of concept with our first-in-class, highly selective IV SMARCA2 degrader, PRT3789, in patients with aggressive SMARCA4 mutated cancers including non-small cell lung cancer (NSCLC) and esophageal cancers as monotherapy. We also demonstrated an encouraging early safety profile with no overlapping toxicities in our ongoing PRT3789 combination study with docetaxel. We are focused on completing monotherapy dose escalation and rapidly enrolling combination arms to support advancement of PRT3789 into next phase of development, initially in these two cancer types.”
Dr. Vaddi continued, “Additional accomplishments for the quarter include the commencement of patient enrollment for our first-in-class, highly selective oral SMARCA2 degrader, PRT7732 in a biomarker selected phase 1 trial. With two highly differentiated SMARCA2 degraders in the clinic, we are well-positioned to build on our leadership in this novel and important therapeutic class and provide optionality for patients. We look forward to reporting our progress on both of these programs beginning early 2025.”
Dr. Vaddi also added, “Other milestones for the quarter included presentation of first preclinical data from our Precision ADC program demonstrating the potential of SMARCA2/4 degrader as a potent and effective payload on multiple antibodies, as well as acceptance of interim clinical data in hematological malignancies of our potential best-in-class CDK9 inhibitor, PRT2527 at the American Society of Hematology Meeting in December.”
Clinical Program Updates and Upcoming Milestones
PRT3789 – A first-in-class, highly selective, intravenous SMARCA2 Degrader
PRT3789 is designed to treat patients with a SMARCA4 mutation. Patients with SMARCA4-mutated cancer have a poor prognosis. This represents an area of high unmet medical need.
PRT3789 is in Phase 1 clinical development in patients with biomarker selected SMARCA4-mutated cancers. Enrollment remains on track, and the Company expects to conclude monotherapy dose escalation by year-end 2024 and identify a dose for advancement to registrational trials. In addition, enrollment of patients into back-fill cohorts enriched for NSCLC and SMARCA4 loss-of-function mutations is ongoing, as is enrollment of the combination with docetaxel cohort. The Company also initiated a Phase 2 clinical trial evaluating PRT3789 in combination with KEYTRUDA® (pembrolizumab) in patients with SMARCA4-mutated cancers, per the previously announced collaboration with Merck (known as MSD outside of the US and Canada).
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Interim Phase 1 data presented at medical congresses in Q3 2024
The Company presented the first interim clinical data updates of the Phase 1 dose escalation study of PRT3789 in SMARCA4 mutated cancers at ESMO Congress 2024 and the 36th EORTC-NCI-AACR Symposium. The presentations can be found at Publications - Prelude Therapeutics.
As reported by investigators, PRT3789 was generally safe and well-tolerated at doses tested to date. Of the 26 advanced NSCLC or esophageal patients with Class 1 (loss of function) mutations who were evaluable for efficacy, RECIST confirmed partial responses (PRs) were observed in 4 patients (2 esophageal, 2 NSCLC). Of the 9 patients with Class 1 mutations treated at doses of 283 mg or higher, two had RECIST confirmed partial responses and both were NSCLC patients. Tumor shrinkage was observed in patients with both Class 1 and Class 2 SMARCA4 mutations. Additional patients on-study demonstrated clinical benefit as measured by prolonged SD, including one advanced NSCLC patient who remains stable and on study having been treated for more than a year.
Initial observations of safety from evaluable patients in the PRT3789 plus docetaxel combination dose escalation arm of the trial were also presented. To date, PRT3789 in combination with docetaxel demonstrated an acceptable safety profile, with no dose limiting toxicities or study drug serious adverse events reported.
PRT7732 – A potent, highly selective and orally bioavailable SMARCA2 Degrader
PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader. The Company initiated and enrolled our first patients in a phase 1 multi-dose escalation trial of PRT7732 (NCT06560645) in biomarker selected SMARCA4 mutated cancers.
Pfizer Ignite Collaboration
Prelude has entered into a collaboration agreement with Pfizer Ignite enabling streamlined access to Ignite services in support of Prelude’s SMARCA2 degrader development programs. Per Pfizer, Ignite is a service offering providing partners access to Pfizer’s significant resources, scale and expertise in developing potentially breakthrough medicines. Under the terms of the collaboration agreement, Prelude retains full ownership and global license rights to all of its programs.
Precision ADC with SMARCA2/4 dual degrader payload
Prelude is developing potent SMARCA2/4 dual degraders that robustly inhibit cancer cell growth and induce cell death across multiple cancer types. The Company presented the first preclinical data from its Precision ADC platform at the 36th EORTC-NCI-AACR Symposium in October. The data demonstrated potent activity of a SMARCA 2/4 degrader payload when conjugated to a range of commercially available antibodies, including PSMA, TROP2, C-MET, CEACAM5, and CD33. The SMARCA2/4 degrader payload conjugated to an anti-PSMA antibody demonstrated tumor regressions and significantly better in vivo efficacy compared to a traditional PSMA-targeted cytotoxic ADC in xenograft models of prostate cancer at well tolerated doses. The presentation can be found at Publications - Prelude Therapeutics.
PRT2527 – A potent and highly selective CDK9 Inhibitor
PRT2527 is a potent and highly selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitors. The Company is currently advancing PRT2527 as monotherapy in both lymphoid and myeloid hematological malignancies, and in combination with zanubrutinib in B-cell malignancies.
PRT2527 is expected to complete monotherapy dose escalation in B-cell malignancies this year. Initiation of dose escalation in myeloid malignancies occurred in the first half of 2024. Interim phase 1 clinical data with potentially best-in-class CDK9 inhibitor, PRT2527 in hematological malignancies will be presented at the American Society of Hematology Annual Meeting in December 2024.
Third Quarter 2024 Financial Results
Cash, Cash Equivalents, and Marketable securities:
Cash, cash equivalents and marketable securities as of September 30, 2024 were
Research and Development (R&D) Expenses:
For the third quarter of 2024, R&D expense increased to
General and Administrative (G&A) Expenses:
For the third quarter of 2024, G&A expenses increased to
Net Loss:
For the three months ended September 30, 2024, net loss was
About Prelude Therapeutics
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. Our corporate presentation can be found at Events & Presentations - Prelude Therapeutics. For more information, visit preludetx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Prelude’s product candidates, the potential safety, efficacy, benefits and addressable market for Prelude’s product candidates, the expected timeline for initial proof-of-concept data and clinical trial results for Prelude’s product candidates, and the sufficiency of Prelude’s cash runway into 2026. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” “schedule,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company’s current expectations and projections about future events and various assumptions. Although Prelude believes that the expectations reflected in such forward-looking statements are reasonable, Prelude cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Prelude's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Prelude's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Prelude’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Prelude's ability to fund development activities and achieve development goals, Prelude's ability to protect intellectual property, and other risks and uncertainties described under the heading "Risk Factors" in Prelude’s Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Reports on Form 10-Q and other documents that Prelude files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Prelude undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.
PRELUDE THERAPEUTICS INCORPORATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
| Three Months Ended September 30, | ||||||||
| (in thousands, except share and per share data) | 2024 | 2023 | ||||||
| Revenue from license agreement | $ | 3,000 | $ | — | ||||
| Operating expenses | ||||||||
| Research and development | 29,457 | 26,261 | ||||||
| General and administrative | 7,919 | 7,124 | ||||||
| Total operating expenses | 37,376 | 33,385 | ||||||
| Loss from operations | (34,376) | (33,385) | ||||||
| Other income, net | 2,105 | 2,777 | ||||||
| Net loss | $ | (32,271) | $ | (30,608) | ||||
| Per share information: | ||||||||
| Net loss per share of common stock, basic and diluted | $ | (0.43) | $ | (0.45) | ||||
| Weighted average common shares outstanding, basic and diluted | 75,855,949 | 67,639,993 | ||||||
| Comprehensive loss: | ||||||||
| Net loss | $ | (32,271) | $ | (30,608) | ||||
| Unrealized gain (loss) on marketable securities, net of tax | 457 | 106 | ||||||
| Comprehensive loss | $ | (31,814) | $ | (30,502) | ||||
PRELUDE THERAPEUTICS INCORPORATED
BALANCE SHEETS
| (in thousands, except share data) | September 30, 2024 | December 31, 2023 | ||||||
| Assets | (unaudited) | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 11,134 | $ | 25,291 | ||||
| Marketable securities | 142,492 | 207,644 | ||||||
| Prepaid expenses and other current assets | 2,761 | 2,654 | ||||||
| Total current assets | 156,387 | 235,589 | ||||||
| Restricted cash | 4,044 | 4,044 | ||||||
| Property and equipment, net | 7,202 | 7,325 | ||||||
| Operating lease right-of-use asset | 29,182 | 30,412 | ||||||
| Other assets | 405 | 295 | ||||||
| Total assets | $ | 197,220 | $ | 277,665 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 5,921 | $ | 4,580 | ||||
| Accrued expenses and other current liabilities | 13,579 | 15,768 | ||||||
| Operating lease liability | 2,365 | 1,481 | ||||||
| Finance lease liability | 359 | — | ||||||
| Total current liabilities | 22,224 | 21,829 | ||||||
| Other liabilities | 3,153 | 3,339 | ||||||
| Operating lease liability | 15,412 | 15,407 | ||||||
| Total liabilities | 40,789 | 40,575 | ||||||
| Commitments | ||||||||
| Stockholders’ equity: | ||||||||
| Voting common stock, | 4 | 4 | ||||||
| Non-voting common stock, | 1 | 1 | ||||||
| Additional paid-in capital | 711,091 | 693,252 | ||||||
| Accumulated other comprehensive income | 167 | 223 | ||||||
| Accumulated deficit | (554,832) | (456,390) | ||||||
| Total stockholders’ equity | 156,431 | 237,090 | ||||||
| Total liabilities and stockholders’ equity | $ | 197,220 | $ | 277,665 | ||||
Investor Contact:
Robert A. Doody, Jr.
Senior Vice President, Investor Relations
Prelude Therapeutics Incorporated
484.639.7235
rdoody@preludetx.com
FAQ
What were Prelude Therapeutics (PRLD) Q3 2024 financial results?
What clinical progress did PRLD report for PRT3789 in Q3 2024?
What is the status of PRLD's cash runway as of Q3 2024?
